Printer Friendly

FDA REQUESTS ADDITIONAL DATA ON MENTOR'S URETHRIN

 FDA REQUESTS ADDITIONAL DATA ON MENTOR'S URETHRIN
 SANTA BARBARA, Calif., Nov. 13 /PRNewswire/ -- Mentor Corp.


(NASDAQ: MNTR) announced today that the U.S. Food and Drug Administration (FDA) has issued a letter stating that the company must submit additional clinical data on Urethrin before the product can be approved for marketing. Urethrin is Mentor's injectable implant for the treatment of urinary incontinence.
 In previous communications the FDA had indicated that it would approve Urethrin subject to certain requirements, primarily related to labelling. The latest letter imposes new conditions which represent a departure from the FDA's previous position.
 "We are disappointed that the FDA has yet again changed its mind," said Christopher J. Conway, chairman and chief executive officer of Mentor Corp., "but we are no longer surprised at anything the FDA does. Under the present administration the FDA's actions have been arbitrary and unpredictable, and it has become virtually impossible to bring a new medical product to the public.
 "Urethrin has been undergoing FDA review since 1986," Conway said. "We had been hoping to get final approval some time next year, but this new request means approval is unlikely for the next two years.
 "We were not counting on Urethrin approval in the near future," added Conway. "So the company's performance over the next year will not be affected by this additional delay."
 Mentor Corp. produces medical and surgical devices for the specialties of urology, plastic surgery and ophthalmology.
 -0- 11/13/92
 /CONTACT: Christopher J. Conway of Mentor Corp., 805-681-6000/
 (MNTR) CO: Mentor Corp. ST: California IN: MTC SU:


LS-KJ -- LA034 -- 0927 11/13/92 17:32 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1992
Words:269
Previous Article:ULTRA PAC, INC. EXPRESSES CAUTION REGARDING ANALYSTS' EARNINGS ESTIMATES
Next Article:FEDERAL EXPRESS REPORTS OCTOBER VOLUME
Topics:


Related Articles
MENTOR URETHRIN APPROVED IN CANADA FOR TREATMENT OF URINARY INCONTINENCE
ROBERTS PHARMACEUTICAL CORPORATION INFORMED THAT ADDITIONAL INFORMATION IS REQUIRED WITH REGARD TO ITS NEW DRUG APPLICATION FOR PROAMATINE
LXR Biotechnology Inc. Announces That the FDA Will Require Additional Preclinical Data on CP-Cardiosol
AVANIR Reports Progress on FDA's Evaluation of New Drug Application For Docosanol.
Avanir Reports Completion of Data Analysis Requested by FDA for New Drug Application; Information sent to FDA for Final Review.
FDA Requests AVANIR Provide Additional Data For Topical Treatment of Cold Sores.
Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters